RU2004139045A - Последовательности cdr3 t-клеточного рецептора и способы детекции - Google Patents
Последовательности cdr3 t-клеточного рецептора и способы детекции Download PDFInfo
- Publication number
- RU2004139045A RU2004139045A RU2004139045/13A RU2004139045A RU2004139045A RU 2004139045 A RU2004139045 A RU 2004139045A RU 2004139045/13 A RU2004139045/13 A RU 2004139045/13A RU 2004139045 A RU2004139045 A RU 2004139045A RU 2004139045 A RU2004139045 A RU 2004139045A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- oligonucleotide
- group
- seq
- nucleotides
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title claims abstract 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract 7
- 238000001514 detection method Methods 0.000 title claims 3
- 108020004707 nucleic acids Proteins 0.000 claims abstract 12
- 102000039446 nucleic acids Human genes 0.000 claims abstract 12
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 17
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 230000000295 complement effect Effects 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
- 239000002751 oligonucleotide probe Substances 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 101150050863 T gene Proteins 0.000 claims 1
- 238000000376 autoradiography Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pathology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38628702P | 2002-06-05 | 2002-06-05 | |
| US60/386,287 | 2002-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004139045A true RU2004139045A (ru) | 2005-09-10 |
Family
ID=29736145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004139045/13A RU2004139045A (ru) | 2002-06-05 | 2003-06-05 | Последовательности cdr3 t-клеточного рецептора и способы детекции |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1530483B1 (https=) |
| JP (3) | JP2005528910A (https=) |
| CN (1) | CN1674931A (https=) |
| AT (1) | ATE453727T1 (https=) |
| AU (1) | AU2003237437B2 (https=) |
| BR (1) | BR0311578A (https=) |
| CA (1) | CA2485874A1 (https=) |
| DE (1) | DE60330780D1 (https=) |
| IL (2) | IL165194A (https=) |
| MX (1) | MXPA04011646A (https=) |
| NO (1) | NO20044945L (https=) |
| NZ (1) | NZ537403A (https=) |
| PL (1) | PL213315B1 (https=) |
| RU (1) | RU2004139045A (https=) |
| WO (1) | WO2003104407A2 (https=) |
| ZA (1) | ZA200409792B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488652B (zh) | 2006-03-16 | 2014-06-18 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| CN108070644B (zh) * | 2016-11-08 | 2021-06-29 | 国家卫生计生委科学技术研究所 | 一种妊娠高血压的诊断系统 |
| CA3057041A1 (en) | 2017-03-15 | 2018-09-20 | Hyogo College Of Medicine | Novel biomarkers for cancer immunotherapy |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL165071A (en) * | 1990-03-30 | 2008-06-05 | Autoimmune Inc | A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients |
| CA2362099C (en) * | 1999-02-23 | 2014-05-13 | Baylor College Of Medicine | T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
-
2003
- 2003-06-05 CA CA002485874A patent/CA2485874A1/en not_active Abandoned
- 2003-06-05 BR BRPI0311578-0A patent/BR0311578A/pt not_active IP Right Cessation
- 2003-06-05 AU AU2003237437A patent/AU2003237437B2/en not_active Ceased
- 2003-06-05 CN CNA038186314A patent/CN1674931A/zh active Pending
- 2003-06-05 RU RU2004139045/13A patent/RU2004139045A/ru not_active Application Discontinuation
- 2003-06-05 PL PL374723A patent/PL213315B1/pl unknown
- 2003-06-05 WO PCT/US2003/017873 patent/WO2003104407A2/en not_active Ceased
- 2003-06-05 DE DE60330780T patent/DE60330780D1/de not_active Expired - Lifetime
- 2003-06-05 NZ NZ537403A patent/NZ537403A/en not_active IP Right Cessation
- 2003-06-05 EP EP03736888A patent/EP1530483B1/en not_active Expired - Lifetime
- 2003-06-05 JP JP2004511467A patent/JP2005528910A/ja not_active Withdrawn
- 2003-06-05 AT AT03736888T patent/ATE453727T1/de not_active IP Right Cessation
- 2003-06-05 MX MXPA04011646A patent/MXPA04011646A/es not_active Application Discontinuation
-
2004
- 2004-11-12 NO NO20044945A patent/NO20044945L/no not_active Application Discontinuation
- 2004-11-14 IL IL165194A patent/IL165194A/en not_active IP Right Cessation
- 2004-12-02 ZA ZA200409792A patent/ZA200409792B/en unknown
-
2010
- 2010-04-01 JP JP2010085593A patent/JP2010207226A/ja not_active Withdrawn
- 2010-06-27 IL IL206650A patent/IL206650A/en not_active IP Right Cessation
-
2013
- 2013-03-05 JP JP2013042552A patent/JP2013126420A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL206650A (en) | 2016-10-31 |
| NO20044945L (no) | 2004-12-28 |
| NZ537403A (en) | 2009-10-30 |
| MXPA04011646A (es) | 2005-03-07 |
| EP1530483A2 (en) | 2005-05-18 |
| BR0311578A (pt) | 2007-04-27 |
| JP2005528910A (ja) | 2005-09-29 |
| EP1530483B1 (en) | 2009-12-30 |
| PL374723A1 (en) | 2005-10-31 |
| JP2010207226A (ja) | 2010-09-24 |
| CN1674931A (zh) | 2005-09-28 |
| JP2013126420A (ja) | 2013-06-27 |
| AU2003237437A1 (en) | 2003-12-22 |
| DE60330780D1 (de) | 2010-02-11 |
| IL206650A0 (en) | 2011-07-31 |
| ATE453727T1 (de) | 2010-01-15 |
| PL213315B1 (pl) | 2013-02-28 |
| AU2003237437B2 (en) | 2010-11-25 |
| WO2003104407A3 (en) | 2005-03-24 |
| EP1530483A4 (en) | 2006-05-17 |
| WO2003104407A2 (en) | 2003-12-18 |
| IL165194A (en) | 2010-11-30 |
| IL165194A0 (en) | 2005-12-18 |
| CA2485874A1 (en) | 2003-12-18 |
| ZA200409792B (en) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5705333A (en) | Peptide-based nucleic acid mimics(PENAMS) | |
| US8206925B2 (en) | Splice variants of human IL-23 receptor (IL-23R) mRNA and use of a delta 9 isoform in predicting inflammatory bowel diseases | |
| Asarnow et al. | Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells | |
| de Mollerat et al. | A genomic rearrangement resulting in a tandem duplication is associated with split hand–split foot malformation 3 (SHFM3) at 10q24 | |
| US20050010030A1 (en) | T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis | |
| ATE353975T1 (de) | Diagnose von mit apoptose assoziierten erkrankungen mittels ermittlung des methylierungszustandes von apoptose-assozierten genen | |
| US20040248090A1 (en) | Method for the parallel detection of the degree of methylation of genomic dna | |
| WO2004063706A2 (en) | Method of detecting over-expression of t-cell receptor genes by real-time pcr | |
| RU2001125895A (ru) | Vбета-Dбета-Jбета-последовательность Т-клеточного рецептора и способы ее обнаружения | |
| Tuffery‐Giraud et al. | Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects | |
| JP2005537007A5 (https=) | ||
| ATE486956T1 (de) | T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis | |
| RU2004139045A (ru) | Последовательности cdr3 t-клеточного рецептора и способы детекции | |
| CA2416545A1 (en) | Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia | |
| Wang et al. | A method for the quantitative analysis of human heat shock gene expression using a multiplex RT-PCR assay | |
| JP2005528910A5 (https=) | ||
| RU2005127807A (ru) | Применение нового полиморфизма в гене hsgki для диагностики гипертонии и применение генов семейства sgk для диагностики и терапии синдрома удлиненного q/t-периода | |
| Grewal et al. | Cloning of the murine unconventional myosin gene Myo9b and identification of alternative splicing | |
| KR102115941B1 (ko) | 대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도 | |
| JP4242590B2 (ja) | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 | |
| Mäueler et al. | The (gt) n (ga) m containing intron 2 of HLA-DRB alleles binds a zinc-dependent protein and forms non B-DNA structures | |
| KR102039529B1 (ko) | 대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도 | |
| WO2007010258A2 (en) | Polymorphism in cysteine dioxygenase | |
| Pinducciu et al. | Toxix thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs� | |
| KR102115933B1 (ko) | 대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080606 |